P I Industries Ltd Q1 FY2024 Concall Summary

Key Takeaways

• Strong quarter despite industry headwinds: Revenue grew 24% YoY, driven by 37% export growth, while domestic business contracted 13% on delayed monsoon.
• Margins expanded meaningfully: EBITDA rose 35% on favorable product mix and operating leverage; gross margin excluding pharma jumped 201 bps.
• Pharma acquisition closed, integration underway: The ₹856 crore Archimica/Therachem deal was completed; management targets 14-15% initial margins, maturing to 20-24%+ over more than a year.
• Guidance cautiously held: Management remains cautiously optimistic on 18-20% revenue growth for FY24, with pharma contribution on top, but will review after the kharif season.
• What to watch next quarter: Whether domestic demand sustains its July recovery through the remainder of kharif, the pace of pharma revenue build-up, and any revision to full-year guidance at the post-Q2 review.

Export Performance & Industry Context

• CSM exports the standout: 33% YoY growth, with 29% from volume and 4% from price, currency and mix; management credits strong endorsement of their early-stage molecule approach.
• Volume growth defies destocking: The 29% volume growth came despite intense global channel destocking because PI's portfolio is early-stage molecules, not mature generics where inventory pileups are concentrated. Farmer-level demand remains strong.
• Chinese deflation a macro overhang: The Chinese economy is exporting deflation through stepped-up chemical exports, impacting the sector across the value chain. Management flagged this as a caution point even as their own portfolio shows resilience.
• No deferment seen: No purchase order deferments in the ongoing quarter, and management does not see significant inventory challenges in the products they export.

Mayank Singhal: "The Chinese economy is experiencing slack domestic demand, and it is exporting deflation through stepped up exports of goods. It is already impacting the chemical sector across the value chain."

Domestic Business & Recovery

• Monsoon hit Q1: Domestic revenue contracted 13% YoY on volume degrowth from delayed rainfall; management focused on qualitative revenue and margins over volumes, keeping tight control on trade working capital.
• Early recovery signal: Demand from July onwards has come out stronger, but only 1.5 months of data is available. Management is cautious, needing to see the remainder of the kharif season before calling a recovery.
• Product launch momentum: Launched EKETSU, India's first three-way herbicide mixture for total weed control in rice, in Q1; five innovative products planned for FY24.
• Biologicals growing: Biological products growing in double digits; two launches planned this year, one in July/August and one in Q3.

Rajnish Sarna: "You see this is not a very advanced industry per se from the agriculture and rural fields or even in the global arena, collecting updated inventory data from the rural markets is not easy and there is always a lead and lag, so we have to be a little cautious and careful in even reading these data points."

Pharma Acquisition & Integration

• Deal closed: Completed acquisition of Archimica and Therachem Group for ₹856 crore during the quarter; integration covers three pieces: Archimica (Italy), TRM (US & India), and a newly built Hyderabad Research Center.
• Margin trajectory: Initial phase expecting 14-15% margins; on maturity targeting 20-24%+ margins, which will take more than a year. Pharma gross margin was 75% but the segment posted an EBITDA loss of ₹5.4 crore due to one-time acquisition and integration costs plus IndAS-115 impact.
• Revenue build-up: Gradual quarter-on-quarter business build-up expected; management confident of meeting expectations in coming quarters. The acquired Indian entity was not previously accounting as per IndAS, complicating like-to-like comparisons.
• Growth ambition: Management wants to more than double the acquired pharma business in the next 3-4 years; further bolt-on M&A being evaluated from remaining QIP funds.
• Differentiation: PI will cover end-to-end pipeline from key starting material to API, complementing its legacy of complex chemistry, digitization and automated manufacturing.

Anil Jain: "At PI, we would cover end-to-end pipeline starting from the key starting material to API. This is complementing the PI legacy of complex chemistry, digitization and automated manufacturing environment of basic chemical manufacturing."

Margins & Working Capital

• Margin drivers: The few hundred bps improvement from last year's 22.5-23% level came mainly from operating leverage and favorable product mix, particularly in domestic business where management focused on quality of revenue over volumes.
• CSM margin confidence: Management confident of sustaining 24-25% margins given visibility of business plans, volume and value.
• Working capital improved: Trade working capital improved to 83 days from 102 days; inventory reduced to ~73 days from 89 days. Management sees further scope for improvement in some business areas.

Rajnish Sarna: "We are confident that given the kind of visibility of business plans, volume, and value that we have, we should be able to sustain these margins."

New Growth Vectors

• Electronic chemicals: Good traction with enquiry pipeline in advanced development stage; commercializing 4-5 molecules. Not expected to be significant in the near term; in five years could reach a few percentage points of revenue but will not become as large as Agchem.
• Biological products: Two launches planned this year; business growing in double digits and expected to continue.
• ESG embedded in strategy: ESG and environmental considerations are part of PI's strategy across every facet: Agchem brand, CSM manufacturing, Health Sciences, and automotive electronics.
• Industry tailwind: India's AgChem exports expected to double in the coming 3-4 years; government considering a PLI scheme for chemicals and AgChem.

Guidance & Commitments

Key Metrics